HealthInvest Partners AB Sells 13,440 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

HealthInvest Partners AB lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 71,138 shares of the biopharmaceutical company's stock after selling 13,440 shares during the period. Intra-Cellular Therapies makes up about 2.8% of HealthInvest Partners AB's investment portfolio, making the stock its 13th biggest holding. HealthInvest Partners AB owned about 0.07% of Intra-Cellular Therapies worth $5,939,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Avior Wealth Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 3.0% in the third quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company's stock valued at $327,000 after buying an additional 131 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company's stock valued at $748,000 after acquiring an additional 141 shares during the last quarter. CIBC Asset Management Inc lifted its stake in Intra-Cellular Therapies by 5.3% in the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company's stock valued at $247,000 after acquiring an additional 150 shares during the last quarter. Pallas Capital Advisors LLC lifted its stake in Intra-Cellular Therapies by 6.4% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company's stock valued at $266,000 after acquiring an additional 192 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Intra-Cellular Therapies by 9.1% in the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock valued at $181,000 after purchasing an additional 207 shares during the period. Institutional investors own 92.33% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ITCI. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Piper Sandler reissued a "neutral" rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their target price for the company from $119.00 to $132.00 in a report on Friday, January 31st. JPMorgan Chase & Co. raised their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an "overweight" rating in a report on Monday, November 4th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Ten research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $106.08.

Intra-Cellular Therapies Trading Down 0.2 %

NASDAQ:ITCI traded down $0.21 during mid-day trading on Thursday, hitting $128.25. 1,278,873 shares of the company's stock were exchanged, compared to its average volume of 3,911,228. The company has a 50 day simple moving average of $112.80 and a 200-day simple moving average of $90.87. Intra-Cellular Therapies, Inc. has a fifty-two week low of $63.30 and a fifty-two week high of $129.00. The firm has a market capitalization of $13.64 billion, a P/E ratio of -147.41 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. As a group, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.60% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.